BDX Stock Down Despite New Expansion to Boost Fingertip Blood Testing

Zacks12-18

Becton, Dickinson and Company BDX, popularly known as BD, and Babson Diagnostics announced an expansion of fingertip blood collection and testing technologies for use by U.S. health systems and other ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492708135?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0y7pHAbd2ah0Qunql6MeVQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b35c1538fbd501bfb8e20b349661fde7","is_english":true,"pubTime":"2024-12-18 23:43","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2492708135","market":"us","top_or_hot":-1,"title":"BDX Stock Down Despite New Expansion to Boost Fingertip Blood Testing","media":"Zacks","content":"<div>\n<p>Becton, Dickinson and Company BDX, popularly known as BD, and Babson Diagnostics announced an expansion of fingertip blood collection and testing technologies for use by U.S. health systems and other ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bdx-stock-down-despite-expansion-154300367.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BDX Stock Down Despite New Expansion to Boost Fingertip Blood Testing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBDX Stock Down Despite New Expansion to Boost Fingertip Blood Testing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 23:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bdx-stock-down-despite-expansion-154300367.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Becton, Dickinson and Company BDX, popularly known as BD, and Babson Diagnostics announced an expansion of fingertip blood collection and testing technologies for use by U.S. health systems and other ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bdx-stock-down-despite-expansion-154300367.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1854104046.USD","symbol_name":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/bdx-stock-down-despite-expansion-154300367.html","article_id":"2492708135","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0y7pHAbd2ah0Qunql6MeVQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b35c1538fbd501bfb8e20b349661fde7"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492708135","pubTimestamp":1734536580,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Becton, Dickinson and Company BDX, popularly known as BD, and Babson Diagnostics announced an expansion of fingertip blood collection and testing technologies for use by U.S. health systems and other large provider networks in settings like urgent cares, doctor offices and other ambulatory care settings. The commercial partnership is an expansion of BD and Babson's collaboration to advance capillary blood testing, which began in 2016 and has since evolved into a strategic partnership.The blood testing process integrates BD's MiniDraw Capillary Blood Collection System with Babson's BetterWay technologies to enable test results from a few drops of capillary blood collected from a patient's finger. With this less-invasive alternative to venipuncture blood draws, samples can be collected and prepared by any trained healthcare worker .The latest expansion is expected to significantly boost BD’s Integrated Diagnostic Solutions  business unit under the broader Life Sciences segment and solidi","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","CAH":"卡地纳健康","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","RMD.AU":"Resmed DRC","BK4504":"桥水持仓","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","BK4548":"巴美列捷福持仓","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4567":"ESG概念","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","BK4585":"ETF&股票定投概念","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LMAT":"勒梅特微管医疗","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","LU1880398554.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) INC","BK4175":"保健护理产品经销商","BDX":"碧迪医疗","LU1880398471.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) ACC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","RMD":"瑞思迈","BK4082":"医疗保健设备","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4588":"碎股","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC"},"translate_title":"尽管新的扩张以促进指尖血液检测，BDX股价仍下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDX":1,"CAH":1,"LMAT":1,"RMD.AU":0.9,"RMD":0.9},"content_text":"Becton, Dickinson and Company BDX, popularly known as BD, and Babson Diagnostics announced an expansion of fingertip blood collection and testing technologies for use by U.S. health systems and other large provider networks in settings like urgent cares, doctor offices and other ambulatory care settings. The commercial partnership is an expansion of BD and Babson's collaboration to advance capillary blood testing, which began in 2016 and has since evolved into a strategic partnership.\nThe blood testing process integrates BD's MiniDraw Capillary Blood Collection System with Babson's BetterWay technologies to enable test results from a few drops of capillary blood collected from a patient's finger. With this less-invasive alternative to venipuncture blood draws, samples can be collected and prepared by any trained healthcare worker (including those without prior phlebotomy experience).\nThe latest expansion is expected to significantly boost BD’s Integrated Diagnostic Solutions (IDS) business unit under the broader Life Sciences segment and solidify its foothold in the niche space.\nLikely Trend of BDX Stock Following the News\nFollowing the announcement yesterday, shares of the company lost nearly 0.8% till yesterday’s closing.\nHistorically, the company has gained a top-line boost from its product launches and various partnerships. Although the announcement of the latest expansion of fingertip blood collection and testing technologies is likely to be beneficial for BDX’s top-line growth going forward, the stock declined overall.\nBD currently has a market capitalization of $65.24 billion. It has an earnings yield of 6.4%, higher than the industry’s 4.9%. In the last reported quarter, BDX delivered an earnings surprise of 1.1%.\nSignificance of the Expansion of BD's Testing Technology\nPer BD, as the majority of clinical decisions are dependent on diagnostic results, blood tests are a routine part of care to aid clinicians in diagnosing, monitoring and treating patients. The capillary solution will likely enable care providers to improve access to blood testing in underserved locations that lack phlebotomy capabilities while lowering common barriers to testing (such as fear of needles and logistical challenges).\nBD’s management believes that simplifying the process of blood collection will make blood testing less invasive and more convenient, helping healthcare organizations increase efficiency and access while improving patient satisfaction and outcomes.\nPer Babson's management, its partnership with BD will likely deliver a potentially transformative technology to support innovative and patient-focused healthcare organizations in better accessing and serving patients.\nIndustry Prospects in Favor of BDX\nPer a report by Grand View Research, the global capillary blood collection devices market was estimated at $2.13 billion in 2024 and is anticipated to witness a CAGR of 8.8% between 2025 and 2030. Factors like the increasing prevalence of chronic, infectious and non-communicable diseases and technological innovations in molecular diagnostic tools are likely to drive the market.\nGiven the market potential, the availability of the blood testing process will likely provide a significant impetus to BD's business.\nBD's Notable Developments\nLast month, BD reported its fourth-quarter fiscal 2024 results, wherein its Life Sciences segment witnessed a revenue uptick on a reported and organic basis and at a constant exchange rate. The segment was aided by its IDS business unit, whose performance reflected strong growth in Specimen Management driven by broad volume strength and strength in BD MAX IVD and BD COR.\nIn October, BD announced Health Canada approval of the BD Onclarity HPV Assay for human papillomavirus (HPV) testing for the use with self-collected vaginal specimens at home.\nBDX's Share Price Performance\nShares of the company have lost 6.2% in the past year against the industry’s 2.9% rise and the S&P 500's 27.9% growth.\nImage Source: Zacks Investment Research\nBD's Zacks Rank & Key Picks\nCurrently, BDX carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the broader medical space are Cardinal Health, Inc. CAH, ResMed Inc. RMD and LeMaitre Vascular, Inc. LMAT.\nCardinal Health, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 10.2%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 11.2%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nCardinal Health’s shares have gained 14.5% compared with the industry’s 2.9% rise in the past year.\nResMed, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.8%. RMD’s earnings surpassed estimates in each of the trailing four quarters, with the average being 6.4%.\nResMed has gained 39.8% compared with the industry’s 12.7% rise in the past year.\nLeMaitre Vascular, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21%. LMAT’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.1%.\nLeMaitre Vascular’s shares have rallied 62.2% compared with the industry’s 12.7% rise in the past year.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBecton, Dickinson and Company (BDX) : Free Stock Analysis Report\nCardinal Health, Inc. (CAH) : Free Stock Analysis Report\nResMed Inc. (RMD) : Free Stock Analysis Report\nLeMaitre Vascular, Inc. (LMAT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492708135"}